Vir Biotechnology (NASDAQ:VIR) Major Shareholder Sells $278,308.16 in Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) major shareholder Endurance (Cayman) Ltd Svf sold 46,696 shares of the stock in a transaction on Friday, October 24th. The stock was sold at an average price of $5.96, for a total value of $278,308.16. Following the transaction, the insider directly owned 14,664,939 shares in the company, valued at approximately $87,403,036.44. This represents a 0.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Endurance (Cayman) Ltd Svf also recently made the following trade(s):

• On Wednesday, October 29th, Endurance (Cayman) Ltd Svf sold 100 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.49, for a total value of $649.00.
• On Tuesday, October 28th, Endurance (Cayman) Ltd Svf sold 24,453 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.50, for a total value of $158,944.50.
• On Monday, October 27th, Endurance (Cayman) Ltd Svf sold 66,403 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.05, for a total value of $401,738.15.
• On Thursday, October 23rd, Endurance (Cayman) Ltd Svf sold 154,383 shares of Vir Biotechnology stock. The stock was sold at an average price of $5.99, for a total value of $924,754.17.
• On Wednesday, October 22nd, Endurance (Cayman) Ltd Svf sold 144,266 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.15, for a total value of $887,235.90.
• On Tuesday, October 21st, Endurance (Cayman) Ltd Svf sold 109,675 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.30, for a total value of $690,952.50.
• On Monday, October 20th, Endurance (Cayman) Ltd Svf sold 220,535 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.20, for a total value of $1,367,317.00.
• On Thursday, October 16th, Endurance (Cayman) Ltd Svf sold 12,844 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.10, for a total value of $78,348.40.
• On Wednesday, October 15th, Endurance (Cayman) Ltd Svf sold 16,671 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.07, for a total value of $101,192.97.
• On Friday, October 10th, Endurance (Cayman) Ltd Svf sold 2,300 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.08, for a total value of $13,984.00.

Vir Biotechnology Stock Up 0.3%

Shares of Vir Biotechnology stock opened at $5.93 on Friday. Vir Biotechnology, Inc. has a fifty-two week low of $4.16 and a fifty-two week high of $14.45. The firm has a market cap of $823.80 million, a PE ratio of -1.48 and a beta of 1.27. The business’s fifty day moving average is $5.46 and its two-hundred day moving average is $5.31.

Vir Biotechnology (NASDAQ:VIR) last issued its earnings results on Wednesday, August 6th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.08). The firm had revenue of $1.21 million during the quarter, compared to analysts’ expectations of $2.38 million. Vir Biotechnology had a negative return on equity of 50.22% and a negative net margin of 2,895.94%.The company’s quarterly revenue was down 60.5% compared to the same quarter last year. During the same period last year, the business posted ($1.02) earnings per share. Equities research analysts anticipate that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently weighed in on VIR shares. Bank of America raised Vir Biotechnology from a “neutral” rating to a “buy” rating and increased their target price for the stock from $12.00 to $14.00 in a research report on Wednesday, August 27th. Raymond James Financial started coverage on Vir Biotechnology in a research report on Friday, July 11th. They issued an “outperform” rating on the stock. Evercore ISI started coverage on Vir Biotechnology in a research report on Wednesday, September 3rd. They issued an “outperform” rating and a $12.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Vir Biotechnology in a research report on Monday, September 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vir Biotechnology in a research report on Tuesday, October 14th. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $17.30.

Institutional Trading of Vir Biotechnology

Several large investors have recently added to or reduced their stakes in VIR. Raymond James Financial Inc. acquired a new stake in Vir Biotechnology in the 2nd quarter valued at $35,000. GAMMA Investing LLC increased its holdings in Vir Biotechnology by 524.3% in the 1st quarter. GAMMA Investing LLC now owns 7,111 shares of the company’s stock valued at $46,000 after purchasing an additional 5,972 shares in the last quarter. Apollon Wealth Management LLC acquired a new stake in Vir Biotechnology in the 2nd quarter valued at $50,000. Daiwa Securities Group Inc. increased its holdings in Vir Biotechnology by 2,200.6% in the 2nd quarter. Daiwa Securities Group Inc. now owns 12,308 shares of the company’s stock valued at $62,000 after purchasing an additional 11,773 shares in the last quarter. Finally, Los Angeles Capital Management LLC acquired a new stake in shares of Vir Biotechnology during the second quarter valued at about $63,000. 65.32% of the stock is currently owned by institutional investors and hedge funds.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).